Changing the Prognosis of Pulmonary Arterial Hypertension: Impact of Medical Therapy

ABSTRACT

Pulmonary arterial hypertension (PAH) is a progressive arteriopathy of the pulmonary circulation that can affect a wide group of patients. Presentation and natural history of PAH are intimately linked to progressive right ventricular failure. Historically, survival in PAH has been poor, especially for patients with PAH associated with progressive systemic sclerosis and human immunodeficiency virus. Oral, subcutaneous, and intravenous therapies that have emerged during the last decade can improve symptoms and hemodynamics. This review explores the impact of these therapies on prognosis in PAH, which ultimately rests on the ability to reverse the pulmonary arteriopathy and preserve right ventricular function.

KEYWORDS

Pulmonary arterial hypertension - prognosis - epoprostenol

REFERENCES

• 1 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
• 2 Rich S, Dantzker D R, Ayres S M et al.. Primary pulmonary hypertension: a national prospective study.  Ann Intern Med. 1987;  107 216-223
• 3 D'Alonzo G E, Barst R J, Ayres S M et al.. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med. 1991;  115 343-349
• 4 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.  N Engl J Med. 1992;  327 76-81
• 5 Fuster V, Steele P M, Edwards W D et al.. Primary pulmonary hypertension: natural history and the importance of thrombosis.  Circulation. 1984;  70 580-587
• 6 Frank H, Mlczoch J, Huber K et al.. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.  Chest. 1997;  112 714-721
• 7 Sandoval J, Bauerle O, Palomar A et al.. Survival in primary pulmonary hypertension: validation of a prognostic equation.  Circulation. 1994;  89 1733-1744
• 8 McLaughlin V V, Presberg K W, Doyle R L et al.. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126 78S-92S
• 9 Stupi A M, Steen V D, Owens G R et al.. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.  Arthritis Rheum. 1986;  29 515-524
• 10 Opravil M, Pechere M, Speich R et al.. HIV-associated primary pulmonary hypertension: a case control study. Swiss HIV Cohort Study.  Am J Respir Crit Care Med. 1997;  155 990-995
• 11 Petitpretz P, Brenot F, Azarian R et al.. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension.  Circulation. 1994;  89 2722-2727
• 12 Nunes H, Humbert M, Sitbon O et al.. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2003;  167 1433-1439
• 13 Hopkins W E, Ochoa L L, Richardson G W, Trulock E P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.  J Heart Lung Transplant. 1996;  15 100-105
• 14 Bristow M R, Zisman L S, Lowes B D et al.. The pressure-overloaded right ventricle in pulmonary hypertension.  Chest. 1998;  114 101S-106S
• 15 Gomez A, Bialostozky D, Zajarias A et al.. Right ventricular ischemia in patients with primary pulmonary hypertension.  J Am Coll Cardiol. 2001;  38 1137-1142
• 16 Louie E K, Rich S, Brundage B H. Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension.  J Am Coll Cardiol. 1986;  8 1298-1306
• 17 Sitbon O, Humbert M, Nunes H et al.. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788
• 18 Raymond R J, Hinderliter A L, Willis P W et al.. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.  J Am Coll Cardiol. 2002;  39 1214-1219
• 19 Torbicki A, Kurzyna M, Kuca P et al.. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension.  Circulation. 2003;  108 844-848
• 20 Nagaya N, Nishikimi T, Uematsu M et al.. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.  Circulation. 2000;  102 865-870
• 21 Yeo T C, Dujardin K S, Tei C, Mahoney D W, McGoon M D, Seward J B. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension.  Am J Cardiol. 1998;  81 1157-1161
• 22 Menzel T, Kramm T, Bruckner A, Mohr-Kahaly S, Mayer E, Meyer J. Quantitative assessment of right ventricular volumes in severe chronic thromboembolic pulmonary hypertension using transthoracic three-dimensional echocardiography: changes due to pulmonary thromboendarterectomy.  Eur J Echocardiogr. 2002;  3 67-72
• 23 Pasque M K, Trulock E P, Kaiser L R, Cooper J D. Single-lung transplantation for pulmonary hypertension: three-month hemodynamic follow-up.  Circulation. 1991;  84 2275-2279
• 24 Hopkins W E, Waggoner A D. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome.  Am J Cardiol. 2002;  89 34-38
• 25 Hinderliter A L, Willis P W, Barst R J et al.. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.  Circulation. 1997;  95 1479-1486
• 26 Badesch D B, Abman S H, Ahearn G S et al.. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126 35S-62S
• 27 Barst R J, Rubin L J, McGoon M D et al.. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.  Ann Intern Med. 1994;  121 409-415
• 28 Barst R J, Rubin L J, Long W A et al.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med. 1996;  334 296-302
• 29 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation. 2002;  106 1477-1482
• 30 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial.  Ann Intern Med. 2000;  132 425-434
• 31 Kuhn K P, Byrne D W, Arbogast P G et al.. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.  Am J Respir Crit Care Med. 2003;  167 580-586
• 32 Kawut S M, Taichman D B, Archer-Chicko C L, Palevsky H I, Kimmel S E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.  Chest. 2003;  123 344-350
• 33 Rosenzweig E B, Kerstein D, Barst R J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation. 1999;  99 1858-1865
• 34 Krowka M J, Frantz R P, McGoon M D et al.. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension.  Hepatology. 1999;  30 641-648
• 35 Tan H P, Markowitz J S, Montgomery R A et al.. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol.  Liver Transpl. 2001;  7 745-749
• 36 Simonneau G, Barst R J, Galie N et al.. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
• 37 Olschewski H, Simonneau G, Galie N et al.. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 38 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 39 McLaughlin V V, Sitbon O, Badesch D B et al.. Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
• 40 Sastry B K, Narasimhan C, Reddy N K, Raju B S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.  J Am Coll Cardiol. 2004;  43 1149-1153
• 41 Farber H W, Loscalzo J. Pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1655-1665
• 42 Humbert M, Barst R J, Robbins I M et al.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359